Neovacs SA Financials
| ALNEV Stock | EUR 0.0002 0.00 0.00% |
Neovacs |
Understanding current and past Neovacs SA Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Neovacs SA's financial statements are interrelated, with each one affecting the others. For example, an increase in Neovacs SA's assets may result in an increase in income on the income statement.
Neovacs SA Stock Summary
Neovacs SA competes with Biomerieux, Eurofins Scientific, Sartorius Stedim, and SEB SA. Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. Neovacs S.A. was founded in 1993 and is based in Paris, France. NEOVACS operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 24 people.| Instrument | France Stock View All |
| Exchange | Euronext Paris |
| ISIN | FR00140077X1 |
| Business Address | 3-5, Impasse Reille, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.neovacs.com |
| Phone | 33 1 53 10 93 00 |
| Currency | EUR - Euro |
You should never invest in Neovacs SA without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Neovacs Stock, because this is throwing your money away. Analyzing the key information contained in Neovacs SA's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Neovacs SA Key Financial Ratios
Neovacs SA's financial ratios allow both analysts and investors to convert raw data from Neovacs SA's financial statements into concise, actionable information that can be used to evaluate the performance of Neovacs SA over time and compare it to other companies across industries.| Return On Equity | -0.27 | |||
| Return On Asset | -0.11 | |||
| Target Price | 1.13 | |||
| Number Of Employees | 21 | |||
| Beta | -0.0405 |
Neovacs Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neovacs SA's current stock value. Our valuation model uses many indicators to compare Neovacs SA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neovacs SA competition to find correlations between indicators driving Neovacs SA's intrinsic value. More Info.Neovacs SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neovacs SA's earnings, one of the primary drivers of an investment's value.Neovacs SA Systematic Risk
Neovacs SA's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Neovacs SA volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Neovacs SA correlated with the market. If Beta is less than 0 Neovacs SA generally moves in the opposite direction as compared to the market. If Neovacs SA Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Neovacs SA is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Neovacs SA is generally in the same direction as the market. If Beta > 1 Neovacs SA moves generally in the same direction as, but more than the movement of the benchmark.
Neovacs SA November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Neovacs SA help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Neovacs SA. We use our internally-developed statistical techniques to arrive at the intrinsic value of Neovacs SA based on widely used predictive technical indicators. In general, we focus on analyzing Neovacs Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Neovacs SA's daily price indicators and compare them against related drivers.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 100.0 | |||
| Value At Risk | (33.33) | |||
| Potential Upside | 33.33 |
Additional Tools for Neovacs Stock Analysis
When running Neovacs SA's price analysis, check to measure Neovacs SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neovacs SA is operating at the current time. Most of Neovacs SA's value examination focuses on studying past and present price action to predict the probability of Neovacs SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neovacs SA's price. Additionally, you may evaluate how the addition of Neovacs SA to your portfolios can decrease your overall portfolio volatility.